BC

Specifically, as the concentration increased from 2.0 µg/mL to 16.0 µg/mL, the viability of gastric cancer cells BGC-823 significantly decreased... 8.0 µg/mL of BB/BC strongly inhibited the viability of cancer cells BGC-823

8.0 µg/mL of BB/BC strongly inhibited the viability of cancer cells BGC-823 while having minimal effect on its corresponding human normal gastric epithelial cells, GES-1

treatment with BC also showed a similar trend with scratch-healing rates of 55.45% and 39.46%, respectively

treatment with BC also showed a similar trend with scratch-healing rates of 55.45% and 39.46%, respectively

the LDH release rate in BGC-823 cells increased from 103.68% to 163.8% at the same concentrations of BC.

the LDH release rate in BGC-823 cells increased from 103.68% to 163.8% at the same concentrations of BC.

treatment with BC at the same concentrations led to even higher apoptotic rates of BGC-823 cells, reaching 28.31%, 31.46%, and 51.61%, respectively

treatment with BC at the same concentrations led to even higher apoptotic rates of BGC-823 cells, reaching 28.31%, 31.46%, and 51.61%, respectively

treatment with BC at the same concentrations led to even higher apoptotic rates of BGC-823 cells, reaching 28.31%, 31.46%, and 51.61%, respectively

a dose-dependent increase in the DCFH positive ratio was also observed in the same cancer cells treated with BC, reaching 28.5%, 61.57%, and 89.38% after 24 h exposure to 4, 6, and 8 µg/mL of BC, respectively.

a dose-dependent increase in the DCFH positive ratio was also observed in the same cancer cells treated with BC, reaching 28.5%, 61.57%, and 89.38% after 24 h exposure to 4, 6, and 8 µg/mL of BC, respectively.

a dose-dependent increase in the DCFH positive ratio was also observed in the same cancer cells treated with BC, reaching 28.5%, 61.57%, and 89.38% after 24 h exposure to 4, 6, and 8 µg/mL of BC, respectively.